Inclusion Criteria

Inclusion criteria:

- Histologically or cytologically confirmed unresectable or metastatic gastric
adenocarcinoma including adenocarcinoma of gastroesophageal junction, which have
failed 2 prior chemotherapy regimens. (For countries where a standard of care has not
been established for the 2nd line treatment for advanced gastric cancer, those who
failed 1 or 2 prior chemotherapy regimens can be included)

- Signed informed consent

Exclusion criteria:

- Patients who have received >2 prior systemic chemotherapy regimens for advanced
gastric cancer.

- For patients entering part 2, those without at least one measurable lesion at
baseline according to Response Evaluation Criteria in Solid Tumors 1.1 criteria

- Eastern Cooperative Oncology Group performance status >1

- Age <18 years

- Inadequate organ and bone marrow function

- Prior surgery, chemotherapy, targeted agents, investigational agents, or other
anti-cancer therapy within 4 weeks prior to enrollment in the study

- Prior radiation therapy within 6 weeks prior to enrollment (except palliative
radiation for a local pain control)

- Previous treatment with cabazitaxel

- Known brain or leptomeningeal involvement of cancer

- Patients with known acquired immunodeficiency syndrome (AIDS) related illness or
known HIV infection requiring antiretroviral treatment.

- Patients with active varicella zoster infection, or known hepatitis B or C infection.

- History of severe hypersensitivity reaction ≥ grade 3 to drugs formulated with
polysorbate 80 such as docetaxel

The above information is not intended to contain all considerations relevant to a
patient's potential participation in a clinical trial.